Literature DB >> 7833499

Effects of gliclazide on fibrin network.

D P Dhall1, C H Nair.   

Abstract

Fibrin network structure is altered by diabetes, peripheral vascular disease, and by some drugs. The antidiabetic drug, gliclazide, increases fibrin fiber thickness but reduces whole network permeability. The networks are, however, more lysable. These effects are further examined in this study using electron microscopy. Changes were observed in protein concentrations in fibrin fibers, in fibrin fiber alignment and in fiber porosity. These results show that gliclazide modifies fibrin monomer polymerization so that the fibrin network is rendered more susceptible to fibrinolysis. This pharmacological action of gliclazide may be useful in the treatment of thromboembolism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7833499     DOI: 10.1016/1056-8727(94)90049-3

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  2 in total

1.  Ligneous conjunctivitis: biochemical evidence for hypofibrinolysis.

Authors:  M L Ramsby; P C Donshik; G S Makowski
Journal:  Inflammation       Date:  2000-02       Impact factor: 4.092

2.  Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.

Authors:  Rodney D Averett; David G Norton; Natalie K Fan; Manu O Platt
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.